KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

News provided by

KemPharm, Inc.

Dec 11, 2018, 08:08 ET

CELEBRATION, Fla., Dec. 11, 2018 /PRNewswire/ -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., presented at an interactive online investor conference. An archive of the event is now available for on-demand viewing at VirtualInvestorConferences.com.

LINK:  https://tinyurl.com/126postpr 

KemPharm's presentation will be available for 90 days.  In addition, investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

Virtual Conference Highlights:

  • On track to file for approval of its lead product candidate, KP415, which is intended for the treatment of attention deficit hyperactivity disorder (ADHD), as soon as the first quarter of 2019;
  • Added new prodrug product candidate, KP879, which is intended for the treatment of stimulant use disorder (SUD);
  • Announced license agreement with KVK Tech for U.S. rights to commercialize FDA-approved APADAZ®;
  • Announced technology collaboration with twoXAR, Inc. to develop novel prodrugs for multiple indications; and
  • Provided an update on the partnering process for KP415 and KP484

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) technology.  KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.  KemPharm's product pipeline is focused on the high need areas of ADHD, pain and other central nervous system disorders.  KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing extended-release/effect profiles.  In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.  For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

About VirtualInvestorConferences.com:

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm's business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2017, and KemPharm's other Periodic and Current Reports filed with the Securities and Exchange Commission.  KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE KemPharm, Inc.

Related Links

http://www.kempharm.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED